Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Live Q&A: Making the Switch from Biologics to Biosimilars in IBD: Knowledge Over Skepticism

Premiere Date: Tuesday, March 22, 2022

This activity will offer CE credit for:

  1. Medicine (accme)
  2. Nursing (ANCC)
  3. Pharmacy (acpe)
  4. PA (aapa)

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Creditâ„¢

Credit Expiration Date:
Wednesday, March 22, 2023
Note: Credit Is No Longer Available


Edward V. Loftus, Jr., MDEdward V. Loftus, Jr., MD (Moderator)
Professor of Medicine
Mayo Clinic College of Medicine
Co-Director, Advanced IBD Fellowship
Mayo Graduate School of Medicine
Consultant, Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, MN

Shubha Bhat, PharmD, MS, BCACPShubha Bhat, PharmD, MS, BCACP 
Clinical Pharmacy Specialist, Gastroenterology
Digestive Disease & Surgery Institute
Cleveland Clinic
Cleveland, OH

Christina Ha, MD, FACG, AGAFChristina Ha, MD, FACG, AGAF 
Inflammatory Bowel Disease Center
Mayo Clinic
Scottsdale, AZ

Statement of Need

Although biosimilars have existed for nearly a decade clinicians and patients have not had full awareness and knowledge of these treatments, often leading to misconceptions about their efficacy and safety. As these biosimilars become available in the United States, it is important to replace the misinformation and unfounded skepticism with evidence-based data on efficacy, safety, and potential cost savings with biosimilar treatments for the management of inflammatory bowel disease (IBD).

This live Q&A session is your opportunity to ask faculty experts about biosimilars in the IBD setting. Join Drs. Edward V. Loftus, Jr.; Shubha Bhat; and Christina Ha to learn about the concepts behind the biosimilar approval pathway as well as interchangeability, extrapolation, substitution, switching, and efficacy and safety data. To view the full activity ahead of this live Q&A, click here.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Define terminology related to biosimilar products, including interchangeability, substitution, and switching.
  • Assess the efficacy and safety of biosimilars via clinical trial data and real-world evidence in regard to treatment selection for patients with IBD.
  • Implement team-based strategies to enhance patient-clinician SDM regarding the use of biosimilars.

Financial Support

This activity is supported by educational funding provided by Amgen.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in gastroenterology and/or primary care

Credit Information

Specific CE Credit information is not available at this time. Please check again soon!

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Loftus reports the following financial relationships:

Consultant: AbbVie Inc.; Amgen Inc; Arena Pharmaceuticals; Boehringer Ingelheim; Bristol Myers Squibb; Calibr - California Institute for Biomedical Research; Celgene Corporation; Eli Lilly; Genentech; Gilead Sciences, Inc; Gossamer Bio; Iterative Scopes, Inc; Janssen Therapeutics; Ono Pharmaceutical Co., LT; Pfizer Inc; Scipher Medicine Corporation; Sunovion Pharmaceuticals, Inc; Takeda Pharmaceutical Company Limited; and UCB, Inc.

Research support: AbbVie Inc.; BIOCOM CRO (Roberts Clinical Trials); Bristol Myers Squibb; Celgene Corporation; Genentech; Gilead Sciences, Inc.; Gossamer Bio; Janssen Therapeutics; Pfizer Inc; Receptos; Takeda Pharmaceutical Company Limited; Theravance; and UCB, Inc.

Stock shareholder (directly purchased): Exact Sciences Corporation

Other financial or material support: Chief Medical Editor, Healio

Dr. Bhat reports no financial relationships.

Dr. Ha reports the following financial relationships:

Advisory Boards/Consultant: AbbVie Inc.; Bristol Myers Squibb; Genentech; Index Pharmaceuticals; Janssen Therapeutics; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Educational grants: Pfizer Inc.

Non-funded research support: AbbVie Inc.; Eli Lilly; Genentech; and Pfizer Inc.

The following CME Outfitters staff have no financial relationships to report:

  • Susan Perry (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download